---
provider: openscientist
model: openscientist-autonomous
cached: false
start_time: '2026-10-12T18:23:54.287214'
end_time: '2026-10-12T19:08:50.831965'
duration_seconds: 2696.54
template_file: templates/disease_pathophysiology_research.md
template_sha: "1e7ea4ee817acfe1dda5f77fafe6f2e8b5927666"
template_variables:
  disease_name: Trichorhinophalangeal Syndrome Type I
  mondo_id: MONDO:0008596
  category: Mendelian
provider_config:
  timeout: 3600
  max_retries: 3
  parameters:
    allowed_domains: []
    max_iterations: 5
    use_hypotheses: false
    investigation_mode: autonomous
    poll_interval: 30
    timeout: 3600
    save_artifacts: true
    artifact_max_bytes: 5242880
citation_count: 39
reference_validation:
  total_references: 43
  verified: 43
  not_found: 0
  unverifiable: 0
  confabulation_rate: 0.0
  quotes_checked: 4
  quotes_valid: 4
  relevance_assessed: 43
  on_topic: 30
  validator_version: 0.3.0
term_validation:
  total_terms: 43
  verified: 39
  not_found: 0
  obsolete: 0
  unverifiable: 4
  confabulation_rate: 0.0
  labels_checked: 16
  labels_matching: 7
  labels_mismatched: 8
  mislabelled_terms:
  - term_id: MONDO:0008596
    reported_labels:
    - MONDO
    ontology_label: trichorhinophalangeal syndrome type I
  - term_id: HP:0045025
    reported_labels:
    - lateral eyebrow thinning
    ontology_label: Narrow palpebral fissure
  - term_id: NCIT:C1898
    reported_labels:
    - Recombinant Human Growth Hormone
    ontology_label: Physical Carcinogens
  - term_id: NCIT:C1476
    reported_labels:
    - Bisphosphonate
    ontology_label: Denileukin Diftitox
  - term_id: NCIT:C47641
    reported_labels:
    - Minoxidil
    ontology_label: Orphenadrine Citrate
  - term_id: NCIT:C15300
    reported_labels:
    - Orthopedic Surgery
    ontology_label: Photodynamic Therapy
  - term_id: NCIT:C51818
    reported_labels:
    - Tooth Extraction
    ontology_label: Coordinating Investigator
  - term_id: NCIT:C15648
    reported_labels:
    - Genetic Counseling
    ontology_label: Continuous Infusion Procedure
  labels_variant: 1
  unresolvable_prefixes:
  - ORPHA
  - Taxon
  needs_review: true
  adapter: 'ols:'
  validator_version: 0.4.5
artifact_count: 2
artifact_sources:
  openscientist_artifacts_zip: 2
artifacts:
- filename: final_report.html
  path: Trichorhinophalangeal_Syndrome_Type_I-deep-research-openscientist_artifacts/final_report.html
  media_type: text/html
  source: openscientist_artifacts_zip
  data_storage_id: null
  description: OpenScientist final report
- filename: final_report.pdf
  path: Trichorhinophalangeal_Syndrome_Type_I-deep-research-openscientist_artifacts/final_report.pdf
  media_type: application/pdf
  source: openscientist_artifacts_zip
  data_storage_id: null
  description: OpenScientist final report
---

## Question

# Disease Characteristics Research Template

## Target Disease
- **Disease Name:** Trichorhinophalangeal Syndrome Type I
- **MONDO ID:** MONDO:0008596 (if available)
- **Category:** Mendelian

## Research Objectives

Please provide a comprehensive research report on **Trichorhinophalangeal Syndrome Type I** covering all of the
disease characteristics listed below. This report will be used to populate a disease knowledge
base entry. Be thorough and cite primary literature (PMID preferred) for all claims.

For each section, **suggested databases/resources** are listed. These are the first places
you should search for information on each topic.

---

### 1. Disease Information
> **Search first:** OMIM, Orphanet, ICD-10/ICD-11, MeSH, PubMed

- What is the disease? Provide a concise overview.
- What are the key identifiers? (OMIM, Orphanet, ICD-10/ICD-11, MeSH, Mondo)
- What are the common synonyms and alternative names?
- Is the information derived from individual patients (e.g., EHR) or aggregated disease-level resources?

### 2. Etiology

- **Disease Causal Factors**: What are the primary causes? (genetic, environmental, infectious, mechanistic)
- **Risk Factors**:
  > **Search first:** PubMed, Cochrane Library, UpToDate, clinical guidelines, ClinVar, ClinGen, GWAS Catalog, PheGenI, CTD, CDC, WHO, epidemiological databases
  - Genetic risk factors (causal variants, susceptibility loci, modifier genes)
  - Environmental risk factors (toxins, lifestyle, occupational exposures, age, sex, family history)
- **Protective Factors**:
  > **Search first:** PubMed, Cochrane Library, clinical trial databases, GWAS Catalog, gnomAD, WHO, CDC, nutrition databases
  - Genetic protective factors (protective variants, modifier alleles)
  - Environmental protective factors (diet, lifestyle, exposures that reduce risk)
- **Gene-Environment Interactions**: How do genetic and environmental factors interact to influence disease?
  > **Search first:** CTD, PubMed, PheGenI, GxE databases

### 3. Phenotypes
> **Search first:** HPO (Human Phenotype Ontology), OMIM, Orphanet, PubMed, clinicaltrials.gov, MedDRA, SNOMED CT, DECIPHER, LOINC

For each phenotype, provide:
- **Phenotype type**: symptoms, clinical signs, physical manifestations, behavioral changes, or laboratory abnormalities
  > For symptoms/signs: HPO, OMIM, Orphanet, PubMed
  > For behavioral changes: HPO, DSM, RDoC (Research Domain Criteria), PubMed
  > For laboratory abnormalities: LOINC, SNOMED CT, LabTests Online, PubMed
- **Phenotype characteristics**:
  > **Search first:** OMIM, Orphanet, HPO, PubMed
  - Age of symptom onset (neonatal, childhood, adult-onset, late-onset)
  - Symptom severity (mild, moderate, severe, variable)
  - Symptom progression (stable, progressive, episodic, fluctuating)
  - Frequency among affected individuals (percentage or qualitative)
- **Quality of life impact**: Effects on daily functioning and well-being (per-phenotype when possible)
  > **Search first:** EQ-5D database, SF-36, WHO QOL databases, PubMed
- Suggest HPO (Human Phenotype Ontology) terms for each phenotype

### 4. Genetic/Molecular Information

- **Causal Genes**: Gene mutations or chromosomal abnormalities responsible for disease (gene symbols, OMIM IDs)
  > **Search first:** OMIM, ClinVar, HGMD, Ensembl, NCBI Gene
- **Pathogenic Variants**:
  - Affected genes (gene symbols, HGNC IDs)
    > **Search first:** OMIM, NCBI Gene, Ensembl, HGNC, UniProt, GeneCards
  - Variant classification (pathogenic, likely pathogenic, VUS per ACMG/AMP guidelines)
    > **Search first:** ClinVar, ClinGen, ACMG/AMP guidelines, VarSome
  - Variant type/class (missense, frameshift, nonsense, splice-site, structural)
  - Allele frequency in population databases
    > **Search first:** gnomAD, 1000 Genomes, ExAC, TOPMed, dbSNP
  - Somatic vs germline origin
    > **Search first:** COSMIC (somatic), ClinVar, ICGC, TCGA
  - Functional consequences (loss of function, gain of function, dominant negative)
- **Modifier Genes**: Genes that modify disease severity or expression
- **Epigenetic Information**: DNA methylation, histone modifications, chromatin changes affecting disease
  > **Search first:** ENCODE, Roadmap Epigenomics, MethBase, DiseaseMeth
- **Chromosomal Abnormalities**: Large-scale genetic changes (aneuploidy, translocations, inversions)
  > **Search first:** DECIPHER, ClinVar, ECARUCA, UCSC Genome Browser

### 5. Environmental Information

- **Environmental Factors**: Non-genetic contributing factors (toxins, radiation, pollution, occupational exposure)
  > **Search first:** CTD (Comparative Toxicogenomics Database), TOXNET, PubMed, EPA databases
- **Lifestyle Factors**: Behavioral factors (smoking, diet, exercise, alcohol consumption)
  > **Search first:** CDC databases, WHO, PubMed, NHANES
- **Infectious Agents**: If applicable, pathogens causing or triggering disease (bacteria, viruses, fungi, parasites)
  > **Search first:** NCBI Taxonomy, ViPR, BV-BRC, MicrobeDB, GIDEON

### 6. Mechanism / Pathophysiology

**Present this section as an ordered causal chain first, then the detail below.**
Open with a numbered sequence of mechanistic steps running from the initiating
lesion (mutation, exposure, infection) to the clinical manifestation, one step per
line, each naming what it causes next. State the causal verb explicitly ("leads
to", "results in") and say where a step is inferred rather than demonstrated.
Where the mechanism branches, show the branch. The categories below are a
checklist of what to cover within those steps, not the organizing structure —
a step may draw on several of them, and a category may contribute to several
steps.

- **Molecular Pathways**: Specific signaling cascades or biochemical pathways involved (Wnt, MAPK, mTOR, PI3K-AKT, etc.)
  > **Search first:** KEGG, Reactome, WikiPathways, PathBank, BioCyc
- **Cellular Processes**: Cell-level mechanisms (apoptosis, autophagy, cell cycle dysregulation, inflammation, etc.)
  > **Search first:** Gene Ontology (GO), Reactome, KEGG, PubMed
- **Protein Dysfunction**: How protein structure or function is altered (misfolding, aggregation, loss of function, gain of function)
  > **Search first:** UniProt, PDB (Protein Data Bank), InterPro, Pfam, AlphaFold
- **Metabolic Changes**: Alterations in metabolic processes (energy metabolism, lipid metabolism, amino acid metabolism)
  > **Search first:** KEGG, BioCyc, HMDB (Human Metabolome Database), BRENDA
- **Immune System Involvement**: Role of immune response (autoimmunity, immunodeficiency, chronic inflammation)
  > **Search first:** ImmPort, Immunome Database, IEDB, Gene Ontology
- **Tissue Damage Mechanisms**: How tissues/ are injured (oxidative stress, ischemia, fibrosis, necrosis)
  > **Search first:** PubMed, Gene Ontology, Reactome
- **Biochemical Abnormalities**: Specific molecular defects (enzyme deficiencies, receptor dysfunction, ion channel defects)
  > **Search first:** BRENDA, UniProt, KEGG, OMIM, PubMed
- **Epigenetic Changes**: DNA methylation, histone modifications affecting gene expression in disease
  > **Search first:** ENCODE, Roadmap Epigenomics, MethBase, DiseaseMeth
- **Molecular Profiling** (if available):
  - Transcriptomics/gene expression changes
    > **Search first:** GEO (Gene Expression Omnibus), ArrayExpress, GTEx, Human Cell Atlas, SRA
  - Proteomics findings
    > **Search first:** PRIDE, ProteomeXchange, Human Protein Atlas, STRING, BioGRID
  - Metabolomics signatures
    > **Search first:** MetaboLights, Metabolomics Workbench, HMDB, METLIN
  - Lipidomics alterations
    > **Search first:** LIPID MAPS, SwissLipids, LipidHome, Metabolomics Workbench
  - Genomic structural features
    > **Search first:** UCSC Genome Browser, Ensembl, NCBI, dbVar, DGV
- **Advanced Technologies** (if applicable):
  - Single-cell analysis findings (cell-type specific mechanisms, cellular heterogeneity)
    > **Search first:** Human Cell Atlas, Single Cell Portal, GEO, CELLxGENE
  - Spatial transcriptomics findings
    > **Search first:** GEO, Spatial Research, Vizgen, 10x Genomics data
  - Multi-omics integration results
    > **Search first:** TCGA, ICGC, cBioPortal, LinkedOmics, PubMed
  - Functional genomics screens (CRISPR, RNAi)
    > **Search first:** DepMap, GenomeRNAi, PubMed, BioGRID ORCS

For each mechanism, describe:
- The causal chain from initial trigger to clinical manifestation
- Which mechanisms are upstream vs downstream
- What cell types and biological processes are involved
- Suggest GO terms for biological processes and CL terms for cell types

### 7. Anatomical Structures Affected

- **Organ Level**:
  - Primary organs directly affected
  - Secondary organ involvement (complications, secondary effects)
  - Body systems involved (cardiovascular, nervous, digestive, respiratory, endocrine, etc.)
  > **Search first:** Uberon, FMA (Foundational Model of Anatomy), OMIM, HPO, ICD-11, MeSH, SNOMED CT
- **Tissue and Cell Level**:
  - Specific tissue types affected (epithelial, connective, muscle, nervous)
  - Specific cell populations targeted (with Cell Ontology terms)
  > **Search first:** Uberon, Human Protein Atlas, Cell Ontology, Human Cell Atlas, CellMarker, PanglaoDB
- **Subcellular Level**:
  - Cellular compartments involved (mitochondria, nucleus, ER, lysosomes) (with GO Cellular Component terms)
  > **Search first:** Gene Ontology (Cellular Component), UniProt, Human Protein Atlas
- **Localization**:
  - Specific anatomical sites (with UBERON terms)
    > **Search first:** FMA, Uberon, NeuroNames (for brain), SNOMED CT
  - Lateralization (unilateral, bilateral, asymmetric)
    > **Search first:** HPO, clinical literature, imaging databases

### 8. Temporal Development

- **Onset**:
  - Typical age of onset (congenital, pediatric, adult, geriatric)
  - Onset pattern (acute, subacute, chronic, insidious)
  > **Search first:** OMIM, Orphanet, HPO, PubMed
- **Progression**:
  - Disease stages (early, intermediate, advanced, end-stage)
    > **Search first:** Cancer Staging Manual (AJCC), WHO classifications, PubMed
  - Progression rate (rapid, slow, variable)
  - Disease course pattern (episodic, relapsing-remitting, progressive, stable)
  - Disease duration (self-limited, chronic lifelong)
  > **Search first:** Disease registries, longitudinal cohort databases, natural history studies, PubMed, Orphanet, OMIM
- **Patterns**:
  - Remission patterns (spontaneous, treatment-induced)
    > **Search first:** Clinical trial databases, disease registries, PubMed
  - Critical periods (time windows of vulnerability or opportunity for intervention)
    > **Search first:** PubMed, developmental biology databases, clinical guidelines

### 9. Inheritance and Population

- **Epidemiology**:
  - Prevalence (cases per 100,000 at given time)
  - Incidence (new cases per 100,000 per year)
  > **Search first:** Orphanet, CDC, WHO, GBD (Global Burden of Disease), national registries, SEER, disease registries
- **For Genetic Etiology**:
  - Inheritance pattern (AD, AR, X-linked, mitochondrial, multifactorial, polygenic)
    > **Search first:** OMIM, Orphanet, ClinVar, GTR (Genetic Testing Registry)
  - Penetrance (complete, incomplete, age-dependent)
    > **Search first:** ClinVar, OMIM, PubMed, ClinGen
  - Expressivity (variable, consistent)
    > **Search first:** OMIM, ClinVar, PubMed
  - Genetic anticipation (increasing severity in successive generations)
    > **Search first:** OMIM, PubMed (especially for repeat expansion disorders)
  - Germline mosaicism
    > **Search first:** ClinVar, OMIM, genetic counseling literature, PubMed
  - Founder effects (population-specific mutations)
    > **Search first:** gnomAD, population genetics databases, PubMed
  - Consanguinity role
    > **Search first:** OMIM, population studies, genetic counseling resources
  - Carrier frequency
    > **Search first:** gnomAD, carrier screening databases, GeneReviews, GTR
- **Population Demographics**:
  - Affected populations (ethnic or demographic groups with higher prevalence)
    > **Search first:** gnomAD, 1000 Genomes, PAGE Study, PubMed, population registries
  - Geographic distribution (endemic areas, regional variation)
    > **Search first:** WHO, CDC, GBD, Orphanet, geographic epidemiology databases
  - Geographic distribution of specific variants
  - Sex ratio (male:female)
    > **Search first:** Disease registries, OMIM, PubMed, epidemiological databases
  - Age distribution of affected individuals
    > **Search first:** CDC, disease registries, SEER, Orphanet

### 10. Diagnostics

- **Clinical Tests**:
  - Laboratory tests (blood, urine, tissue chemistry, specific enzyme assays)
    > **Search first:** LOINC, LabTests Online, PubMed
  - Biomarkers (proteins, metabolites, genetic markers, circulating biomarkers)
    > **Search first:** FDA Biomarker List, BEST (Biomarkers, EndpointS, and other Tools), PubMed
  - Imaging studies (X-ray, CT, MRI, PET, ultrasound)
    > **Search first:** RadLex, DICOM, Radiopaedia, imaging databases
  - Functional tests (pulmonary function, cardiac stress tests)
    > **Search first:** LOINC, clinical guidelines, PubMed
  - Electrophysiology (EEG, EMG, ECG, nerve conduction studies)
    > **Search first:** LOINC, clinical neurophysiology databases, PubMed
  - Biopsy findings (histopathology, immunohistochemistry)
    > **Search first:** SNOMED CT, College of American Pathologists resources, PubMed
  - Pathology findings (microscopic examination)
    > **Search first:** SNOMED CT, Digital Pathology databases, PubMed
- **Genetic Testing**:
  > **Search first:** GTR (Genetic Testing Registry), GeneReviews, ClinGen
  - Overview of recommended genetic testing approach
  - Whole genome sequencing (WGS) utility
    > **Search first:** GTR, ClinVar, GEL (Genomics England), gnomAD
  - Whole exome sequencing (WES) utility
    > **Search first:** GTR, ClinVar, OMIM, GeneMatcher
  - Gene panels (which panels, which genes)
    > **Search first:** GTR, ClinVar, laboratory-specific databases
  - Single gene testing
    > **Search first:** GTR, ClinVar, OMIM, GeneReviews
  - Chromosomal microarray (CMA)
    > **Search first:** DECIPHER, ClinVar, dbVar, ECARUCA
  - Karyotyping
    > **Search first:** Chromosome Abnormality Database, ClinVar, cytogenetics resources
  - FISH
    > **Search first:** ClinVar, cytogenetics databases, PubMed
  - Mitochondrial DNA testing
    > **Search first:** MITOMAP, MSeqDR, ClinVar, GTR
  - Repeat expansion testing
    > **Search first:** GTR, ClinVar, repeat expansion databases, PubMed
- **Omics-Based Diagnostics** (if applicable):
  - RNA sequencing / transcriptomics
    > **Search first:** GEO, ArrayExpress, GTEx, RNA-seq databases
  - Proteomics
    > **Search first:** PRIDE, ProteomeXchange, FDA Biomarker database
  - Metabolomics
    > **Search first:** MetaboLights, Metabolomics Workbench, HMDB
  - Epigenomics
    > **Search first:** GEO, ENCODE, Roadmap Epigenomics, MethBase
  - Liquid biopsy
    > **Search first:** COSMIC, ClinVar, liquid biopsy databases, PubMed
- **Clinical Criteria**:
  - Standardized diagnostic criteria (DSM, ICD, society guidelines)
    > **Search first:** DSM-5, ICD-11, clinical society guidelines, UpToDate
  - Differential diagnosis (other conditions to rule out, with distinguishing features)
    > **Search first:** DynaMed, UpToDate, clinical decision support systems
- **Screening**:
  - Screening methods for asymptomatic individuals (newborn screening, carrier screening, cascade screening)
    > **Search first:** ACMG recommendations, CDC newborn screening, GTR

### 11. Outcome/Prognosis

- **Survival and Mortality**:
  - Survival rate (5-year, 10-year, overall)
    > **Search first:** SEER, cancer registries, disease-specific registries, PubMed
  - Life expectancy (with and without treatment if applicable)
    > **Search first:** Orphanet, disease registries, actuarial databases, PubMed
  - Mortality rate
    > **Search first:** CDC, WHO, GBD, national mortality databases
  - Disease-specific mortality (deaths directly attributable to disease)
    > **Search first:** Disease registries, CDC Wonder, GBD, PubMed
- **Morbidity and Function**:
  - Morbidity (disease-related disability and health impacts)
    > **Search first:** GBD, WHO, disability databases, PubMed
  - Disability outcomes (long-term functional impairments)
    > **Search first:** ICF (International Classification of Functioning), disability registries
  - Quality of life measures (EQ-5D, SF-36, PROMIS, disease-specific tools)
    > **Search first:** EQ-5D database, SF-36, PROMIS, PubMed
- **Disease Course**:
  - Complications (secondary problems: infections, organ failure, etc.)
    > **Search first:** ICD codes, disease registries, clinical databases, PubMed
  - Recovery potential (likelihood and extent of recovery, with vs without treatment)
    > **Search first:** Natural history studies, rehabilitation databases, PubMed
- **Prediction**:
  - Prognostic factors (age, disease severity, biomarkers, treatment response)
    > **Search first:** Prognostic models databases, clinical calculators, PubMed
  - Prognostic biomarkers (molecular markers predicting disease course)
    > **Search first:** FDA Biomarker database, PubMed, cancer prognostic databases

### 12. Treatment

- **Pharmacotherapy**:
  - Pharmacological treatments (drug names, drug classes, mechanisms of action)
    > **Search first:** DrugBank, RxNorm, ATC classification, DailyMed, FDA databases
  - Pharmacogenomics (how genetic variants affect drug metabolism, efficacy, toxicity)
    > **Search first:** PharmGKB, CPIC (Clinical Pharmacogenetics), FDA Table of PGx Biomarkers
- **Advanced Therapeutics**:
  - Gene therapy (viral vectors, CRISPR, gene replacement, gene editing)
    > **Search first:** ClinicalTrials.gov, FDA gene therapy database, ASGCT resources
  - Cell therapy (stem cell transplant, CAR-T, cellular therapeutics)
    > **Search first:** ClinicalTrials.gov, FDA cell therapy database, FACT standards
  - RNA-based therapies (ASOs, siRNA, mRNA therapies)
    > **Search first:** ClinicalTrials.gov, FDA approvals, PubMed
  - Targeted therapies (treatments directed at specific molecular targets)
    > **Search first:** My Cancer Genome, OncoKB, ClinicalTrials.gov, FDA approvals
  - Immunotherapies (checkpoint inhibitors, monoclonal antibodies)
    > **Search first:** Cancer Immunotherapy Database, FDA approvals, ClinicalTrials.gov
- **Surgical and Interventional**:
  - Surgical interventions (types of surgery, timing, outcomes)
    > **Search first:** CPT codes, surgical registries, clinical guidelines, PubMed
- **Supportive and Rehabilitative**:
  - Supportive care (symptom management, pain control, nutrition)
    > **Search first:** Clinical guidelines, Cochrane Library, PubMed
  - Rehabilitation (physical therapy, occupational therapy, speech therapy)
    > **Search first:** Rehabilitation medicine databases, clinical guidelines, PubMed
- **Experimental**:
  - Experimental treatments in clinical trials (with NCT identifiers if available)
    > **Search first:** ClinicalTrials.gov, EU Clinical Trials Register, WHO ICTRP
- **Treatment Outcomes**:
  - Treatment response rates
    > **Search first:** Clinical trial databases, FDA reviews, systematic reviews, PubMed
  - Side effects and adverse events
    > **Search first:** FDA Adverse Event Reporting System (FAERS), MedWatch, PubMed
- **Treatment Strategy**:
  - Treatment algorithms (clinical pathways, decision trees)
    > **Search first:** Clinical practice guidelines, NCCN Guidelines, UpToDate
  - Combination therapies
    > **Search first:** ClinicalTrials.gov, treatment guidelines, PubMed
  - Personalized medicine approaches (genotype-guided treatment)
    > **Search first:** My Cancer Genome, CIViC, PharmGKB, precision medicine databases

For each treatment, suggest NCIT (NCI Thesaurus) clinical-intervention terms where applicable.

### 13. Prevention

- **Prevention Levels**:
  - Primary prevention (preventing disease occurrence: vaccination, risk factor modification)
    > **Search first:** CDC, WHO, USPSTF recommendations, Cochrane Library
  - Secondary prevention (early detection and treatment: screening programs, early intervention)
    > **Search first:** USPSTF, CDC screening guidelines, WHO
  - Tertiary prevention (preventing complications in those with disease)
    > **Search first:** Clinical guidelines, disease management protocols, PubMed
- **Immunization**: Vaccine strategies (if applicable)
  > **Search first:** CDC vaccine schedules, WHO immunization, FDA vaccine database
- **Screening and Early Detection**:
  - Screening programs (population-based: newborn screening, cancer screening)
    > **Search first:** CDC screening programs, USPSTF, cancer screening databases
  - Genetic screening (carrier screening, preimplantation genetic diagnosis, prenatal testing)
    > **Search first:** ACMG recommendations, ACOG guidelines, GTR
  - Risk stratification (identifying high-risk individuals for targeted prevention)
    > **Search first:** Risk prediction models, clinical calculators, PubMed
- **Behavioral Interventions**: Lifestyle modifications to reduce risk
  > **Search first:** CDC, WHO, behavioral intervention databases, Cochrane Library
- **Counseling**: Genetic counseling (risk assessment, family planning guidance)
  > **Search first:** NSGC resources, ACMG guidelines, GeneReviews
- **Public Health**:
  - Public health interventions (sanitation, vector control, health education)
    > **Search first:** CDC, WHO, public health databases, PubMed
  - Environmental interventions (reducing environmental risk factors)
    > **Search first:** EPA databases, WHO environmental health, PubMed
- **Prophylaxis**: Preventive medications or procedures
  > **Search first:** Clinical guidelines, FDA approvals, PubMed

### 14. Other Species / Natural Disease

- **Taxonomy**: Species affected (with NCBI Taxon identifiers)
  > **Search first:** NCBI Taxonomy
- **Breed**: Specific breeds affected (with VBO identifiers if applicable)
  > **Search first:** VBO (Vertebrate Breed Ontology)
- **Gene**: Orthologous genes in other species (with NCBI Gene IDs)
  > **Search first:** NCBI Gene
- **Natural Disease**:
  - Naturally occurring disease in other species (companion animals, wildlife)
    > **Search first:** OMIA (Online Mendelian Inheritance in Animals), VetCompass, PubMed
  - Veterinary relevance and importance in animal health
    > **Search first:** OMIA, veterinary databases, PubMed
- **Comparative Biology**:
  - Comparative pathology (similarities and differences across species)
    > **Search first:** OMIA, comparative pathology databases, PubMed
  - Evolutionary conservation of disease mechanisms
    > **Search first:** HomoloGene, OrthoMCL, Alliance of Genome Resources
- **Transmission** (if applicable):
  - Zoonotic potential
    > **Search first:** CDC zoonotic diseases, WHO zoonoses, GIDEON
  - Cross-species susceptibility
    > **Search first:** NCBI Taxonomy, veterinary databases, PubMed

### 15. Model Organisms

- **Model Types**:
  - Model organism type (mammalian, invertebrate, cellular, in vitro)
    > **Search first:** Alliance of Genome Resources, model organism databases
  - Specific model systems (mouse, rat, zebrafish, Drosophila, C. elegans, yeast, cell lines, organoids, iPSCs)
    > **Search first:** MGI, RGD, ZFIN, FlyBase, WormBase, SGD, ATCC, Cellosaurus
  - Induced models (drug treatment, surgical intervention, environmental manipulation)
    > **Search first:** MGI, model organism databases, PubMed
- **Genetic Models**:
  - Types available (knockout, knock-in, transgenic, conditional, humanized)
    > **Search first:** MGI, IMPC, KOMP, EuMMCR, IMSR
- **Model Characteristics**:
  - Phenotype recapitulation (how well model reproduces human disease features)
    > **Search first:** Model organism databases, comparative studies, PubMed
  - Model limitations (aspects of human disease not captured)
    > **Search first:** Model organism databases, PubMed, review articles
- **Applications**:
  - Research applications (what aspects of disease can be studied)
    > **Search first:** Model organism databases, PubMed
- **Resources**:
  - Model databases
    > **Search first:** MGI, RGD, ZFIN, FlyBase, WormBase, IMSR, EMMA, MMRRC

---

## Citation Requirements

- Cite primary literature (PMID preferred) for all mechanistic and clinical claims
- Prioritize recent reviews and landmark papers
- Include direct quotes from abstracts where possible to support key statements
- Distinguish evidence source types: human clinical, model organism, in vitro, computational

## Output Format

Structure your response as a comprehensive narrative organized by the sections above.
For each section, provide:
- Factual content with specific details (numbers, percentages, gene names, variant nomenclature)
- Ontology term suggestions (HPO, GO, CL, UBERON, CHEBI, NCIT, MONDO) where applicable
- Evidence citations with PMIDs
- Direct quotes from abstracts to support key claims
- Clear indication when information is not available or not applicable for this disease

This report will be used to populate a disease knowledge base entry with:
- Pathophysiology descriptions with causal chains
- Gene/protein annotations (HGNC, GO terms)
- Phenotype associations (HP terms) with frequencies
- Cell type involvement (CL terms)
- Anatomical locations (UBERON terms)
- Chemical entities (CHEBI terms)
- Treatment annotations (NCIT terms)
- Evidence items with PMIDs and exact abstract quotes
- Epidemiology, prognosis, diagnostic, and prevention information
- Animal model descriptions with phenotype recapitulation details


## Output

# Trichorhinophalangeal Syndrome Type I (TRPS I): A Comprehensive Disease-Characterization Report

**Disease:** Trichorhinophalangeal Syndrome Type I
**MONDO ID:** MONDO:0008596 · **OMIM:** 190350 · **Orphanet:** ORPHA:77258 · **Category:** Mendelian (autosomal dominant)
**Causal gene:** *TRPS1* (8q23.3) · **HGNC:** 12340 · **OMIM:** 604386

---

## Summary

Trichorhinophalangeal syndrome type I (TRPS I) is a rare (~1 in 100,000; minimum point prevalence ~0.5/100,000) autosomal-dominant craniofacial–skeletal dysplasia caused by **heterozygous loss-of-function/haploinsufficient variants in *TRPS1***, a gene on chromosome 8q23.3 encoding a GATA-type zinc-finger transcriptional repressor. The disorder is defined by a clinical triad reflected in its name: **tricho** (fine, sparse, slow-growing scalp hair and thin lateral eyebrows), **rhino** (a bulbous, pear-shaped nose with underdeveloped/hypoplastic alae nasi), and **phalangeal** (brachydactyly with pathognomonic cone-shaped epiphyses). Short stature, hip dysplasia, and progressive premature osteoarthrosis round out the phenotype. Intelligence and life expectancy are normal.

Mechanistically, TRPS1 is a master transcriptional regulator of **endochondral ossification, hair-follicle morphogenesis, and odontogenesis**. Reduced TRPS1 activity **de-represses RUNX2, Indian hedgehog (Ihh), SOX9, STAT3, and PTHrP in growth-plate cartilage**, uncoupling chondrocyte differentiation from perichondrial mineralization; it **disrupts a Wnt-inhibitor/transcription-factor network required for hair-follicle development**; and it **dysregulates Dspp-dependent dentin mineralization**. Most pathogenic variants are **truncating (nonsense/frameshift) LOF alleles causing haploinsufficiency**, whereas **missense variants in the exon-6 GATA DNA-binding domain act in a dominant-negative fashion** and produce the more severe, brachydactyly-predominant TRPS III end of the allelic spectrum. TRPS II (Langer–Giedion syndrome) is a contiguous-gene deletion removing *TRPS1* plus *EXT1* (± *RAD21*), adding multiple exostoses and sometimes intellectual disability.

There is no disease-modifying or curative therapy. Management is **symptomatic and multidisciplinary**: recombinant human growth hormone (rhGH) in the subset with documented GH deficiency, bisphosphonates for severe osteoporosis, orthopedic surgery for hip/joint disease, dental care for supernumerary/impacted teeth, and genetic counseling for the 50% transmission risk. TRPS1 biology extends well beyond the clinical triad—to kidney development/fibrosis (BMP7/TGF-β/Smad) and to oncology, where TRPS1 is now a highly sensitive, largely breast-specific immunohistochemistry marker.

---

## Section 1 — Disease Information

**Overview.** TRPS I is a hereditary skeletal dysplasia with a characteristic clinical presentation, classified into types I, II, and III based on phenotype and genotype ([PMID: 21844942](https://pubmed.ncbi.nlm.nih.gov/21844942/)). TRPS I—the most common subtype—is caused by heterozygous mutations in the single gene *TRPS1*; it exhibits distinctive craniofacial, ectodermal, and skeletal abnormalities with **extremely variable expressivity**, such that many mild cases remain undiagnosed ([PMID: 30458885](https://pubmed.ncbi.nlm.nih.gov/30458885/)).

**Key identifiers.**

| Resource | Identifier |
|---|---|
| MONDO | MONDO:0008596 |
| OMIM | 190350 (TRPS I) |
| Orphanet | ORPHA:77258 |
| MeSH | Langer-Giedion Syndrome / Tricho-rhino-phalangeal syndrome |
| ICD-10 | Q87.1 (congenital malformation syndromes predominantly associated with short stature) |
| Gene (HGNC) | *TRPS1*, HGNC:12340, OMIM 604386, locus 8q23.3 (older literature: 8q24.1/8q24.12) |

**Synonyms / alternative names.** Tricho-rhino-phalangeal syndrome type I; TRPS1; TRP syndrome type I; trichorhinophalangeal dysplasia syndrome ([PMID: 3958163](https://pubmed.ncbi.nlm.nih.gov/3958163/)); "Giedion syndrome" is used for the broader TRPS spectrum ([PMID: 37147064](https://pubmed.ncbi.nlm.nih.gov/37147064/)).

**Information source.** The knowledge base here is derived primarily from **aggregated disease-level resources** (OMIM, Orphanet) supplemented by **individual-patient clinical reports and cohort studies** (103-patient international cohort, [PMID: 25792522](https://pubmed.ncbi.nlm.nih.gov/25792522/); 20-child Korean cohort, [PMID: 42361898](https://pubmed.ncbi.nlm.nih.gov/42361898/); 15-patient single-center series, [PMID: 38574886](https://pubmed.ncbi.nlm.nih.gov/38574886/)) and from **mouse/in-vitro mechanistic studies**. No local datasets or EHR data were used; this is a literature synthesis.

---

## Section 2 — Etiology

**Primary cause (genetic).** TRPS I is **monogenic and autosomal dominant**, caused by heterozygous pathogenic variants in *TRPS1*. In an international cohort of 103 molecularly/cytogenetically confirmed patients, TRPS I was present in 85 individuals (22 missense, 62 "other" mutations) versus 14 with TRPS II ([PMID: 25792522](https://pubmed.ncbi.nlm.nih.gov/25792522/)). The review by Saeki et al. states the disorder "occurs in 1 in 100,000 people globally and is caused by several types of mutations of the TRPS1 gene" ([PMID: 40995872](https://pubmed.ncbi.nlm.nih.gov/40995872/)).

**Genetic risk factors.** The causal variant in *TRPS1* is the sole established risk factor. **No susceptibility loci or modifier genes outside *TRPS1* have been established in humans**, though *RUNX2* is a genetic modifier of the growth-plate phenotype in mice (double-heterozygote rescue; [PMID: 18424451](https://pubmed.ncbi.nlm.nih.gov/18424451/)).

**Environmental risk factors.** None known. TRPS I is a Mendelian disorder with no demonstrated environmental or infectious contribution. A substantial fraction of cases are de novo ("fresh") mutations ([PMID: 10405449](https://pubmed.ncbi.nlm.nih.gov/10405449/)).

**Protective factors.** No genetic or environmental protective factors have been described. *Not applicable* for this Mendelian disorder.

**Gene–environment interactions.** None documented. *Not applicable.*

---

## Section 3 — Phenotypes

The phenotype is variable and presents a wide clinical spectrum ([PMID: 31343132](https://pubmed.ncbi.nlm.nih.gov/31343132/)). The defining features, per the 103-patient cohort ([PMID: 25792522](https://pubmed.ncbi.nlm.nih.gov/25792522/)), are **fine/sparse hair, thick medial eyebrows, broad/bulbous nasal ridge and tip, underdeveloped nasal alae, short hands/feet, cone-shaped epiphyses, and reduced linear growth**.

| Phenotype | Type | HPO term (suggested) | Onset | Frequency / severity |
|---|---|---|---|---|
| Sparse, fine, slow-growing scalp hair | Ectodermal/physical | HP:0002213 (sparse hair) | Congenital/childhood | Near-universal; variable; non-terminal hairs, low density ([PMID: 40790426](https://pubmed.ncbi.nlm.nih.gov/40790426/)) |
| Thin lateral eyebrows / thick medial eyebrows | Physical | HP:0045025 (lateral eyebrow thinning) | Childhood | Common; diagnostic clue |
| Bulbous/pear-shaped nose, hypoplastic alae nasi | Physical | HP:0000414 (bulbous nose), HP:0000430 (underdeveloped nasal alae) | Congenital | Near-universal; characteristic |
| Brachydactyly, short metacarpals/phalanges | Skeletal | HP:0001156 (brachydactyly) | Childhood (radiographic) | Near-universal; **severe with exon-6 missense** ([PMID: 42361898](https://pubmed.ncbi.nlm.nih.gov/42361898/)) |
| Cone-shaped epiphyses | Skeletal/radiographic | HP:0010579 (cone-shaped epiphysis) | Childhood | Pathognomonic radiographic sign |
| Short stature | Growth | HP:0004322 (short stature) | Prenatal + postnatal | Common; variable; GH deficiency in a subset |
| Hip dysplasia / Perthes-like changes | Skeletal | HP:0001385 (hip dysplasia) | Childhood–adult | Frequent; dominant morbidity ([PMID: 3958163](https://pubmed.ncbi.nlm.nih.gov/3958163/)) |
| Progressive premature osteoarthrosis | Skeletal | HP:0002758 (osteoarthritis) | Childhood → adult | **100% in one cohort** ([PMID: 38574886](https://pubmed.ncbi.nlm.nih.gov/38574886/)); progressive |
| Osteopenia / low bone mass | Skeletal/lab | HP:0000938 (osteopenia) | Childhood–adult | Common ([PMID: 25792522](https://pubmed.ncbi.nlm.nih.gov/25792522/)) |
| Dental anomalies (supernumerary/impacted teeth, microdontia) | Physical | HP:0011069 (supernumerary tooth), HP:0000699 (microdontia) | Childhood | Variable; up to 45 teeth reported ([PMID: 37147064](https://pubmed.ncbi.nlm.nih.gov/37147064/)) |
| Protruding ears | Physical | HP:0000411 (protruding ear) | Congenital | Common |

**Age of onset.** Most features are **congenital or manifest in childhood**; radiographic cone-shaped epiphyses appear in childhood; joint disease often precedes diagnosis and can present as late as adulthood (>40 years; [PMID: 3958163](https://pubmed.ncbi.nlm.nih.gov/3958163/)).

**Progression.** Craniofacial and digital features are **stable/structural**; joint disease and osteoarthrosis are **progressive**.

**Quality-of-life impact.** The dominant QoL burden is **lifelong joint disease**—reported by all patients in one cohort, often before diagnosis ([PMID: 38574886](https://pubmed.ncbi.nlm.nih.gov/38574886/))—plus cosmetic concerns (hair, nose, stature) and dental complications. Formal EQ-5D/SF-36 data are not available for TRPS I (*knowledge gap*).

---

## Section 4 — Genetic / Molecular Information

**Causal gene.** *TRPS1* (8q23.3; OMIM 604386), encoding a **GATA-type transcription factor with nine zinc-finger motifs** that functions primarily as a **transcriptional repressor** ([PMID: 21630221](https://pubmed.ncbi.nlm.nih.gov/21630221/)).

**Pathogenic variants — spectrum and classification.** Most variants are **truncating loss-of-function**. In the landmark mutation survey, "seven of the nine mutations result in a premature stop codon, leading to a truncated, nonfunctional TRPS1 protein. The final two mutations are missense mutations in the GATA DNA binding zinc finger" ([PMID: 11950061](https://pubmed.ncbi.nlm.nih.gov/11950061/)). The Korean cohort reported **truncating 65%, exon-6 missense 15%, exonic deletions 20%** ([PMID: 42361898](https://pubmed.ncbi.nlm.nih.gov/42361898/)).

Representative variants (all ACMG pathogenic/likely-pathogenic, germline, heterozygous):

| Variant (cDNA / protein) | Type | Phenotype note | PMID |
|---|---|---|---|
| c.2086C>T (p.Arg696Ter) | Nonsense | Classic TRPS I, familial | [30458885](https://pubmed.ncbi.nlm.nih.gov/30458885/) |
| c.2854_2858del (p.Asn952ArgfsTer2) | Frameshift | TRPS I, 4-generation family | [36093893](https://pubmed.ncbi.nlm.nih.gov/36093893/) |
| c.880_882delAAG | In-frame del | Disturbed RUNX2/STAT3 repression | [36990068](https://pubmed.ncbi.nlm.nih.gov/36990068/) |
| c.2783A>G (p.Tyr928Cys) | Missense (GATA domain) | **Severe** brachydactyly + short stature | [30914275](https://pubmed.ncbi.nlm.nih.gov/30914275/) |
| c.2762G>A (p.Arg921Gln) | Missense | Dental anomalies, impaired dentin mineralization | [32442662](https://pubmed.ncbi.nlm.nih.gov/32442662/) |
| p.Ala932Ser (exon 6, GATA) | Missense | TRPS III | [28468609](https://pubmed.ncbi.nlm.nih.gov/28468609/) |
| c.3809_3811delACTinsCATGTTGTG | Indel (Ikaros-like ZnF) | TRPS I + supernumerary teeth | [27706911](https://pubmed.ncbi.nlm.nih.gov/27706911/) |

**Functional consequences.** Truncating variants → **haploinsufficiency (LOF)**. **GATA-domain missense variants act as dominant-negatives**, disturbing the protein's transcriptional repression of targets such as RUNX2 and STAT3 despite normal cellular localization and expression ([PMID: 36990068](https://pubmed.ncbi.nlm.nih.gov/36990068/)).

**Allele frequency.** Pathogenic *TRPS1* variants are private/rare and essentially absent from population databases (gnomAD); the disorder is fully penetrant and dominant.

**Modifier genes.** *RUNX2* dosage modifies the skeletal phenotype in mouse models (double-heterozygote rescue; [PMID: 18424451](https://pubmed.ncbi.nlm.nih.gov/18424451/)). No validated human modifiers.

**Epigenetic information.** No disease-specific DNA-methylation/histone signature has been defined for TRPS I (*knowledge gap*). Note that TRPS1 itself acts on chromatin as a transcriptional regulator.

**Chromosomal abnormalities.** Large deletions at **8q23–q24** cause the contiguous-gene TRPS II (Langer–Giedion), removing *TRPS1*, *RAD21*, and *EXT1*; a ~3.2-Mb critical region defines typical LGS ([PMID: 35290978](https://pubmed.ncbi.nlm.nih.gov/35290978/); [PMID: 41683676](https://pubmed.ncbi.nlm.nih.gov/41683676/)). Intragenic deletions/microdeletions of *TRPS1* alone cause TRPS I.

---

## Section 5 — Environmental Information

**Environmental factors.** None established. TRPS I is purely genetic.
**Lifestyle factors.** None. *Not applicable.*
**Infectious agents.** None. *Not applicable.*

(Any environmental contribution would be limited to general modifiers of growth/bone health; no TRPS-specific data exist.)

---

## Section 6 — Mechanism / Pathophysiology

### Ordered causal chain (initiating lesion → clinical manifestation)

**Skeletal/chondrogenic branch:**
1. A heterozygous *TRPS1* variant (truncating LOF → haploinsufficiency, **or** exon-6 GATA-domain missense → dominant-negative) **results in** reduced functional TRPS1 transcriptional-repressor activity in cartilage.
2. Reduced TRPS1 **leads to** de-repression of its direct targets **RUNX2, SOX9, STAT3, PTHrP** and increased **Indian hedgehog (Ihh)** expression/signaling in the growth plate ([PMID: 18424451](https://pubmed.ncbi.nlm.nih.gov/18424451/); [PMID: 24709795](https://pubmed.ncbi.nlm.nih.gov/24709795/)).
3. Loss of TRPS1–RUNX2 repression **results in** delayed chondrocyte differentiation but accelerated perichondrial mineralization—i.e., **uncoupling of chondrocyte differentiation from perichondrial mineralization** ([PMID: 18424451](https://pubmed.ncbi.nlm.nih.gov/18424451/)).
4. Dysregulated chondrocyte condensation, proliferation, maturation, apoptosis, and phalangeal-joint formation (downstream of Gdf5 signaling; TRPS1 also directly interacts with activated Gli3) **leads to** abnormal endochondral ossification ([PMID: 24709795](https://pubmed.ncbi.nlm.nih.gov/24709795/)).
5. Abnormal endochondral ossification **results in** the **cone-shaped epiphyses, brachydactyly, short stature, hip dysplasia, and premature osteoarthrosis** observed clinically.

**Hair-follicle branch:**
1. Reduced TRPS1 in dermal papilla / peri-hair-peg mesenchyme **leads to** downregulation of a network of **secreted Wnt inhibitors and transcription factors** and upregulation of extracellular-matrix proteins ([PMID: 22115758](https://pubmed.ncbi.nlm.nih.gov/22115758/)).
2. (TRPS1 here acts as both repressor *and* **direct transcriptional activator**, binding target-gene promoters to activate them — [PMID: 22115758](https://pubmed.ncbi.nlm.nih.gov/22115758/).)
3. Disrupted Wnt-dependent follicle morphogenesis **results in** reduced/absent follicles → **sparse, fine, slow-growing, non-terminal hair** ([PMID: 40790426](https://pubmed.ncbi.nlm.nih.gov/40790426/)).

**Dental branch:**
1. Dysregulated TRPS1 in odontoblasts **alters** direct repression of the **Dspp** promoter and expression of mineralization genes (Alpl, Phospho1) ([PMID: 22508542](https://pubmed.ncbi.nlm.nih.gov/22508542/); [PMID: 25128529](https://pubmed.ncbi.nlm.nih.gov/25128529/)).
2. This **leads to** impaired dentin mineralization and, via APC/RUNX2/Wnt dysregulation, **supernumerary/impacted teeth and dental anomalies** ([PMID: 32442662](https://pubmed.ncbi.nlm.nih.gov/32442662/); [PMID: 27706911](https://pubmed.ncbi.nlm.nih.gov/27706911/)).

*(Steps 2–4 of the skeletal branch are directly demonstrated in mouse models and in-vitro assays; their quantitative applicability to human tissue is inferred.)*

### ASCII schematic

```
TRPS1 variant (LOF haploinsufficiency  OR  GATA-domain dominant-negative)
                 │  ↓ functional TRPS1 repressor activity
    ┌────────────┼───────────────────────────┬──────────────────────┐
    ▼            ▼                             ▼                      ▼
 CARTILAGE    de-repress RUNX2/Ihh/        HAIR FOLLICLE          ODONTOBLAST
 growth       SOX9/STAT3/PTHrP             ↓ Wnt inhibitors       dysreg. Dspp,
 plate        + Gli3 interaction           + TF network           Alpl, Phospho1
    │            │                             │                      │
    ▼            ▼                             ▼                      ▼
 uncoupled chondrocyte diff. vs          disrupted follicle      impaired dentin
 perichondrial mineralization            morphogenesis           mineralization;
    │                                         │                  supernumerary teeth
    ▼                                         ▼                      ▼
 cone-shaped epiphyses, brachydactyly,   sparse/fine/non-        dental anomalies
 short stature, hip dysplasia, OA        terminal hair
```

### Molecular pathways and processes
- **Pathways:** Indian hedgehog (Ihh) signaling; Wnt signaling (via secreted Wnt inhibitors); Gdf5/BMP signaling; TGF-β/Smad (chiefly in kidney). KEGG/Reactome: Hedgehog signaling, Wnt signaling pathway.
- **Cellular processes (GO):** chondrocyte differentiation (GO:0002062), endochondral ossification (GO:0001958), regulation of transcription (GO:0006357), hair follicle morphogenesis (GO:0031069), apoptotic process (GO:0006915), biomineral tissue development (GO:0031214).
- **Protein dysfunction:** truncation → nonfunctional protein (LOF); GATA-domain missense → impaired DNA binding and loss of repression (dominant-negative) ([PMID: 11950061](https://pubmed.ncbi.nlm.nih.gov/11950061/); [PMID: 36990068](https://pubmed.ncbi.nlm.nih.gov/36990068/)).
- **Cell types (CL):** chondrocyte (CL:0000138), odontoblast (CL:0000060), dermal papilla / perichondrial mesenchymal cells, osteoblast (CL:0000062).
- **Pleiotropy beyond the triad:** In kidney, Trps1 acts downstream of Bmp7 in mesenchymal–epithelial transition; its loss activates **TGF-β/Smad3**, suppressing ureteric-bud branching ([PMID: 23537899](https://pubmed.ncbi.nlm.nih.gov/23537899/)), and haploinsufficiency promotes renal fibrosis via increased Arkadia and reduced Smad7 ([PMID: 20507941](https://pubmed.ncbi.nlm.nih.gov/20507941/)). Trps1 also promotes tubular repair after ischemia-reperfusion via Pde4d/AKT ([PMID: 27466160](https://pubmed.ncbi.nlm.nih.gov/27466160/)).
- **Molecular profiling:** Microarray of mutant mouse whisker pads identified downregulated Wnt inhibitors/transcription factors and upregulated ECM proteins ([PMID: 22115758](https://pubmed.ncbi.nlm.nih.gov/22115758/)); ChIP-seq in kidney/cancer contexts confirms direct promoter binding.

---

## Section 7 — Anatomical Structures Affected

**Organ/system level.**
- **Primary:** skeleton (hands, feet, phalanges, hips, long bones), skin appendages (hair follicles), nose/craniofacial structures, teeth.
- **Body systems:** musculoskeletal (dominant), integumentary (ectodermal), craniofacial.
- **Secondary/pleiotropic (chiefly from model organisms):** kidney (development, fibrosis); oncologic relevance (breast and other GATA-factor-expressing tumors).

**UBERON suggestions:** phalanx (UBERON:0003221), epiphysis (UBERON:0006716), hip joint (UBERON:0001464), growth plate (UBERON:0006233), hair follicle (UBERON:0002073), nose (UBERON:0000004), tooth (UBERON:0001091), dentine (UBERON:0001751), kidney (UBERON:0002113).

**Tissue/cell level.** Cartilage (growth-plate chondrocytes, CL:0000138), perichondrium/mesenchyme, dermal papilla and peri-hair-peg mesenchymal cells, odontoblasts (CL:0000060), osteoblasts (CL:0000062).

**Subcellular level (GO Cellular Component).** Nucleus (GO:0005634) — TRPS1 is a nuclear transcription factor with sequence-specific DNA binding at target-gene promoters.

**Localization / lateralization.** Skeletal involvement is **bilateral and generally symmetric** (hands, feet, hips); hair and facial features are midline/bilateral.

---

## Section 8 — Temporal Development

**Onset.** Largely **congenital** facial/ectodermal features; **childhood** radiographic skeletal signs; onset pattern is **chronic/insidious**. Diagnosis is often delayed—median age at diagnosis 15 years in one series ([PMID: 38574886](https://pubmed.ncbi.nlm.nih.gov/38574886/)), with some patients first diagnosed after age 40 ([PMID: 3958163](https://pubmed.ncbi.nlm.nih.gov/3958163/)).

**Progression.** Craniofacial/digital morphology is structurally **stable**. **Joint disease is progressive** — Perthes-like hip dysplasia and "severe and progressive degenerative arthritis" ([PMID: 3958163](https://pubmed.ncbi.nlm.nih.gov/3958163/)); premature osteoarthrosis ([PMID: 3621840](https://pubmed.ncbi.nlm.nih.gov/3621840/)). Growth retardation is prenatal and postnatal.

**Disease course/duration.** **Chronic, lifelong**; non-remitting. No spontaneous remission; interventions (rhGH, bisphosphonates, orthopedic surgery) modify specific complications.

**Critical periods.** The childhood/prepubertal window is key for growth intervention—GH therapy is most effective when initiated earlier and continued longer in prepubertal/early-pubertal stages ([PMID: 36990068](https://pubmed.ncbi.nlm.nih.gov/36990068/)).

---

## Section 9 — Inheritance and Population

**Epidemiology.** Prevalence ~**1 in 100,000** globally ([PMID: 40995872](https://pubmed.ncbi.nlm.nih.gov/40995872/)); **minimum point prevalence 0.5/100,000 (95% CI 0.3–0.8)** in a single-center series ([PMID: 38574886](https://pubmed.ncbi.nlm.nih.gov/38574886/)). Incidence not formally established; many mild cases are undiagnosed.

**Inheritance.** **Autosomal dominant.** Both inherited and de novo ("fresh") mutations occur ([PMID: 10405449](https://pubmed.ncbi.nlm.nih.gov/10405449/)). Transmission risk to offspring is **50%**.

**Penetrance / expressivity.** High penetrance but **markedly variable expressivity**, even within families ([PMID: 25792522](https://pubmed.ncbi.nlm.nih.gov/25792522/); [PMID: 30458885](https://pubmed.ncbi.nlm.nih.gov/30458885/)).

**Genotype–phenotype correlation.** **Exon-6 GATA-domain missense variants → severe brachydactyly** (consistent across cohorts; [PMID: 42361898](https://pubmed.ncbi.nlm.nih.gov/42361898/); [PMID: 30914275](https://pubmed.ncbi.nlm.nih.gov/30914275/)), and define TRPS III. Stature shows no clear genotype correlation ([PMID: 42361898](https://pubmed.ncbi.nlm.nih.gov/42361898/)). Facial features do not differ between TRPS I and II ([PMID: 25792522](https://pubmed.ncbi.nlm.nih.gov/25792522/)).

**Anticipation / mosaicism / founder effects / consanguinity / carrier frequency.** No genetic anticipation (not a repeat-expansion disorder). Germline mosaicism not specifically characterized. No founder effects or consanguinity role (dominant, often de novo). Carrier frequency *not applicable* (dominant).

**Demographics.** Reported worldwide (European, Turkish, Korean, Chinese, Thai, Moroccan, Cypriot cohorts). Female predominance noted in some series (e.g., 73% female; [PMID: 38574886](https://pubmed.ncbi.nlm.nih.gov/38574886/)), likely ascertainment-related rather than a true sex effect. No established sex-ratio bias expected in a dominant disorder.

---

## Section 10 — Diagnostics

**Clinical/radiographic.** Diagnosis is based on **characteristic facial features + sparse hair + brachydactyly with cone-shaped epiphyses on hand/foot X-rays** ([PMID: 21844942](https://pubmed.ncbi.nlm.nih.gov/21844942/)). Cone-shaped epiphyses are the hallmark radiographic sign ([PMID: 42705688](https://pubmed.ncbi.nlm.nih.gov/42705688/)). **Trichoscopy** reveals non-terminal, thin, sparse hairs with low density and increased single-hair follicular units; a **high occipital hairline** is proposed as a diagnostic pearl ([PMID: 40790426](https://pubmed.ncbi.nlm.nih.gov/40790426/)). DXA documents low bone mineral density/osteopenia. Endocrine work-up (GH stimulation tests) identifies the GH-deficient subset ([PMID: 22964620](https://pubmed.ncbi.nlm.nih.gov/22964620/)). Full dental/radiographic examination is recommended to detect supernumerary/impacted teeth ([PMID: 37147064](https://pubmed.ncbi.nlm.nih.gov/37147064/)).

**Genetic testing.** Molecular confirmation by **TRPS1 sequencing** (Sanger / next-generation / whole-exome) is the gold standard ([PMID: 36990068](https://pubmed.ncbi.nlm.nih.gov/36990068/); [PMID: 42705688](https://pubmed.ncbi.nlm.nih.gov/42705688/)). **Chromosomal microarray / molecular karyotyping** detects 8q23–q24 contiguous-gene deletions distinguishing TRPS II ([PMID: 36866988](https://pubmed.ncbi.nlm.nih.gov/36866988/); [PMID: 35290978](https://pubmed.ncbi.nlm.nih.gov/35290978/)). Skeletal-dysplasia NGS panels, CMA, and MLPA are all employed ([PMID: 40626694](https://pubmed.ncbi.nlm.nih.gov/40626694/)). WES is valuable when the clinical picture is atypical or overlaps mimics.

**Clinical criteria / differential diagnosis.** Differentials include **cleidocranial dysplasia** (RUNX2; supernumerary teeth; [PMID: 30095610](https://pubmed.ncbi.nlm.nih.gov/30095610/)), **FBXO11-related IDDFBA syndrome** (TRPS-like facies but with developmental delay; [PMID: 38679370](https://pubmed.ncbi.nlm.nih.gov/38679370/)), juvenile idiopathic arthritis and other skeletal dysplasias presenting with non-inflammatory musculoskeletal complaints ([PMID: 40626694](https://pubmed.ncbi.nlm.nih.gov/40626694/)), and TRPS II/III within the spectrum.

**Screening.** No population newborn screening (rare dominant disorder). **Cascade testing** of at-risk relatives and prenatal/preimplantation testing are feasible once the familial variant is known.

---

## Section 11 — Outcome / Prognosis

**Survival/mortality.** **Life expectancy is normal.** TRPS I is not life-limiting; intelligence is normal in TRPS I ([PMID: 10405449](https://pubmed.ncbi.nlm.nih.gov/10405449/)).

**Morbidity.** The **dominant morbidity is joint disease**—reported by **all patients** in one cohort, often before diagnosis ([PMID: 38574886](https://pubmed.ncbi.nlm.nih.gov/38574886/)); "morbidity mostly concerns joint problems" in the 103-patient cohort ([PMID: 25792522](https://pubmed.ncbi.nlm.nih.gov/25792522/)). Progressive premature osteoarthrosis and Perthes-like hip dysplasia may require hip replacement ([PMID: 3958163](https://pubmed.ncbi.nlm.nih.gov/3958163/); [PMID: 3621840](https://pubmed.ncbi.nlm.nih.gov/3621840/)). Osteopenia/osteoporosis can cause fractures ([PMID: 24357341](https://pubmed.ncbi.nlm.nih.gov/24357341/)).

**Complications.** Degenerative arthritis, hip deformity, fractures from low BMD, dental impaction/malocclusion, short stature. Occasional rare findings: renal cyst/stone ([PMID: 3621840](https://pubmed.ncbi.nlm.nih.gov/3621840/)), cerebral hamartoma/long-bone cysts (rare; [PMID: 36866988](https://pubmed.ncbi.nlm.nih.gov/36866988/)).

**Prognostic factors.** **Exon-6 GATA-domain missense** predicts more severe brachydactyly ([PMID: 42361898](https://pubmed.ncbi.nlm.nih.gov/42361898/); [PMID: 30914275](https://pubmed.ncbi.nlm.nih.gov/30914275/)). GH-deficiency status predicts GH-therapy response ([PMID: 22964620](https://pubmed.ncbi.nlm.nih.gov/22964620/)).

---

## Section 12 — Treatment

**There is no causal/curative treatment; management is symptomatic and supportive**, requiring coordination among pediatrics, endocrinology, orthopedics, dermatology, rehabilitation, and dentistry ([PMID: 21844942](https://pubmed.ncbi.nlm.nih.gov/21844942/); [PMID: 31343132](https://pubmed.ncbi.nlm.nih.gov/31343132/)).

| Intervention | Indication | Evidence | NCIT (suggested) |
|---|---|---|---|
| **Recombinant human GH (rhGH)** | Short stature with documented GH deficiency | Improved growth velocity & radiographic femoral epiphyses ([PMID: 31884116](https://pubmed.ncbi.nlm.nih.gov/31884116/)); 5.7±0.9 cm/yr over 10 yr in GH-deficient patient, poor response if non-deficient ([PMID: 22964620](https://pubmed.ncbi.nlm.nih.gov/22964620/)); improved linear growth over 2 yr in two patients ([PMID: 36990068](https://pubmed.ncbi.nlm.nih.gov/36990068/)) | Recombinant Human Growth Hormone (NCIT:C1898) |
| **Bisphosphonates (IV neridronate)** | Severe osteoporosis / recurrent fractures | Off-label 2 mg/kg q3mo stopped new fractures and raised lumbar BMD by **+45%** ([PMID: 24357341](https://pubmed.ncbi.nlm.nih.gov/24357341/)) | Bisphosphonate (NCIT:C1476) |
| **Minoxidil (topical)** | Hair thinning | Variable response ([PMID: 42361898](https://pubmed.ncbi.nlm.nih.gov/42361898/)) | Minoxidil (NCIT:C47641) |
| **Orthopedic surgery** | Hip dysplasia, degenerative arthritis | Valuable for many ([PMID: 21844942](https://pubmed.ncbi.nlm.nih.gov/21844942/)) | Orthopedic Surgery (NCIT:C15300) |
| **Dental surgery / extraction** | Impacted & supernumerary teeth | 4 third molars + 11 supernumerary teeth removed under GA ([PMID: 37147064](https://pubmed.ncbi.nlm.nih.gov/37147064/)) | Tooth Extraction (NCIT:C51818) |
| **Cosmetic aids, rehabilitation (PT/OT)** | Hair, stature, joint function | Supportive ([PMID: 21844942](https://pubmed.ncbi.nlm.nih.gov/21844942/)) | — |
| **Genetic counseling** | 50% transmission risk | Recommended for patient and family ([PMID: 21844942](https://pubmed.ncbi.nlm.nih.gov/21844942/)) | Genetic Counseling (NCIT:C15648) |

**Pharmacogenomics / advanced therapeutics.** No gene therapy, cell therapy, RNA-based, targeted, or immunotherapy exists for TRPS I. Animal-model work proposes **potential therapeutic targets** in the dysregulated pathways (RUNX2/Ihh, Wnt, TGF-β/Smad) but none are clinically translated ([PMID: 40995872](https://pubmed.ncbi.nlm.nih.gov/40995872/)). No TRPS-specific clinical trials (NCT) are established.

**Treatment outcomes/strategy.** rhGH benefit is **conditional on GH deficiency** ([PMID: 22964620](https://pubmed.ncbi.nlm.nih.gov/22964620/))—a genotype/phenotype-guided (personalized) approach. Earlier, longer GH therapy in prepubertal/early-pubertal stages associates with better height outcomes ([PMID: 36990068](https://pubmed.ncbi.nlm.nih.gov/36990068/)).

---

## Section 13 — Prevention

**Primary prevention.** None possible for a dominant genetic disorder other than **reproductive options**: genetic counseling, prenatal diagnosis, and **preimplantation genetic testing** once the familial *TRPS1* variant is known.

**Secondary prevention.** **Cascade genetic testing** of at-risk relatives enables early diagnosis; early orthopedic, endocrine, and dental surveillance allows timely intervention ([PMID: 30458885](https://pubmed.ncbi.nlm.nih.gov/30458885/); [PMID: 37147064](https://pubmed.ncbi.nlm.nih.gov/37147064/)).

**Tertiary prevention.** Prevent complications: DXA monitoring and bisphosphonates to prevent fractures ([PMID: 24357341](https://pubmed.ncbi.nlm.nih.gov/24357341/)); orthopedic management to delay/manage degenerative arthritis; dental monitoring to prevent impaction complications.

**Immunization / public-health / environmental interventions.** *Not applicable* (non-infectious, non-environmental).

**Counseling.** Genetic counseling is central, emphasizing the 50% transmission risk and variable expressivity ([PMID: 21844942](https://pubmed.ncbi.nlm.nih.gov/21844942/)).

---

## Section 14 — Other Species / Natural Disease

**Taxonomy / orthologs.** *TRPS1* is conserved; the principal experimental ortholog is mouse **Trps1** (*Mus musculus*, NCBI Taxon:10090), with rat (*Rattus norvegicus*, Taxon:10116) used for kidney studies ([PMID: 27466160](https://pubmed.ncbi.nlm.nih.gov/27466160/)).

**Natural disease in other species / breeds.** No naturally occurring TRPS-equivalent disease in companion animals or wildlife is documented in the reviewed literature (OMIA entry *not identified*; *knowledge gap*).

**Comparative biology / evolutionary conservation.** The TRPS1 regulatory functions in cartilage, hair follicle, kidney, and tooth are **evolutionarily conserved**, as mouse models recapitulate human skeletal, hair, and dental phenotypes ([PMID: 40995872](https://pubmed.ncbi.nlm.nih.gov/40995872/); [PMID: 21630221](https://pubmed.ncbi.nlm.nih.gov/21630221/)).

**Transmission / zoonosis.** *Not applicable* (non-communicable genetic disorder).

---

## Section 15 — Model Organisms

Rodent models are central to TRPS research—"several animal models have been established and studied intensively to address this rare disease" ([PMID: 40995872](https://pubmed.ncbi.nlm.nih.gov/40995872/)).

| Model | Type | Phenotype recapitulated | PMID |
|---|---|---|---|
| **Trps1^Δgt/Δgt** (GATA-domain deletion) | Knock-in/deletion | Delayed chondrocyte differentiation, accelerated perichondrial mineralization, ↑Runx2/Ihh; reduced pelage follicles, absent vibrissae, ↓Wnt inhibitors | [18424451](https://pubmed.ncbi.nlm.nih.gov/18424451/); [22115758](https://pubmed.ncbi.nlm.nih.gov/22115758/) |
| **Trps1-null** | Knockout | Early postnatal lethality; expanded renal interstitium, impaired ureteric-bud branching (TGF-β/Smad3) | [23537899](https://pubmed.ncbi.nlm.nih.gov/23537899/) |
| **Trps1^+/−** | Haploinsufficient | Renal tubulointerstitial fibrosis via ↑Arkadia / ↓Smad7 | [20507941](https://pubmed.ncbi.nlm.nih.gov/20507941/) |
| **Trps1^Δint/Δint** (regulatory-element deletion, hypomorph) | Novel knock-in | Postnatal growth retardation, delayed secondary ossification centers, acetabular/hip dysplasia, patellar dislocation | [38899779](https://pubmed.ncbi.nlm.nih.gov/38899779/) |
| **Col1a1-Trps1 transgenic** (overexpression) | Transgenic | Dentinogenesis-imperfecta-like dentin via Dspp-promoter repression | [22508542](https://pubmed.ncbi.nlm.nih.gov/22508542/) |
| **Preodontoblast cell lines** (Trps1-deficient / -overexpressing) | In vitro | Dual role in dentin mineralization (Alpl/Phospho1) | [25128529](https://pubmed.ncbi.nlm.nih.gov/25128529/); [30691926](https://pubmed.ncbi.nlm.nih.gov/30691926/) |

**Model value and limitations.** The **Trps1^Δint hypomorph** is notable for recapitulating *postnatal* hip-joint pathology relevant to the dominant human morbidity ([PMID: 38899779](https://pubmed.ncbi.nlm.nih.gov/38899779/)). A key limitation is that **homozygous null mice are postnatally lethal**, whereas human TRPS I is heterozygous and viable—so dosage-sensitive models (Δgt heterozygotes, hypomorphs) better mirror the human condition. Models have been used to dissect RUNX2/Ihh, Wnt, TGF-β/Smad, and Dspp mechanisms and to nominate therapeutic targets ([PMID: 40995872](https://pubmed.ncbi.nlm.nih.gov/40995872/)). **Resource:** Mouse Genome Informatics (MGI) for *Trps1* alleles.

---

## Mechanistic Model / Interpretation

TRPS1 is best understood as a **dosage-sensitive master transcriptional regulator** of mesenchymal differentiation. The unifying theme across all three cardinal tissues (cartilage, hair, tooth)—and the pleiotropic kidney phenotype—is that **TRPS1 sets the correct timing and level of differentiation programs**, principally by *repressing* key drivers (RUNX2, SOX9, STAT3, PTHrP, Dspp) but also, context-dependently, *activating* others (Wnt inhibitors, FOXA1). When TRPS1 activity falls below a threshold—whether by haploinsufficiency (truncating variants) or dominant-negative poisoning of the GATA domain (exon-6 missense)—these programs become **temporally and quantitatively uncoupled**, producing structural malformation rather than cell death.

The genotype–phenotype gradient is mechanistically coherent: truncating LOF alleles remove one functional copy (milder, classic TRPS I), whereas GATA-domain missense alleles produce a mutant protein that **actively interferes** with DNA binding, yielding more severe brachydactyly and the TRPS III phenotype ([PMID: 11950061](https://pubmed.ncbi.nlm.nih.gov/11950061/); [PMID: 28468609](https://pubmed.ncbi.nlm.nih.gov/28468609/)). TRPS II layers an *EXT1*-deletion exostoses phenotype onto the *TRPS1* deficiency. This single axis—**TRPS1 dosage/function**—thus explains the entire TRPS I/III/II allelic and contiguous-gene spectrum.

---

## Evidence Base

| PMID | Role | Key contribution |
|---|---|---|
| [25792522](https://pubmed.ncbi.nlm.nih.gov/25792522/) | Supports Disease Info, Genotype, Prognosis | 103-patient cohort; mutation spectrum; morbidity = joints |
| [40995872](https://pubmed.ncbi.nlm.nih.gov/40995872/) | Supports Epidemiology, Models | Prevalence ~1/100,000; animal-model synthesis; therapeutic targets |
| [18424451](https://pubmed.ncbi.nlm.nih.gov/18424451/) | Supports Mechanism | Core skeletal mechanism: TRPS1–RUNX2 repression, ↑Ihh, uncoupling |
| [42361898](https://pubmed.ncbi.nlm.nih.gov/42361898/) | Supports Genotype-Phenotype | Exon-6 missense → severe brachydactyly; genotype classes |
| [30914275](https://pubmed.ncbi.nlm.nih.gov/30914275/) | Supports Genotype-Phenotype | GATA-domain missense → severe phenotype |
| [31884116](https://pubmed.ncbi.nlm.nih.gov/31884116/), [22964620](https://pubmed.ncbi.nlm.nih.gov/22964620/) | Support Treatment | rhGH efficacy conditional on GH deficiency |
| [22115758](https://pubmed.ncbi.nlm.nih.gov/22115758/) | Supports Mechanism (hair) | TRPS1 activates Wnt-inhibitor network; dual repressor/activator |
| [32442662](https://pubmed.ncbi.nlm.nih.gov/32442662/), [22508542](https://pubmed.ncbi.nlm.nih.gov/22508542/) | Support Mechanism (dental) | Dental phenotype; Dspp-promoter repression mechanism |
| [38574886](https://pubmed.ncbi.nlm.nih.gov/38574886/) | Supports Epidemiology, Prognosis | Prevalence 0.5/100,000; joint disease in 100% |
| [20507941](https://pubmed.ncbi.nlm.nih.gov/20507941/), [38647255](https://pubmed.ncbi.nlm.nih.gov/38647255/) | Support Pleiotropy | Renal fibrosis (TGF-β/Smad); TRPS1 as breast-cancer IHC marker |
| [24357341](https://pubmed.ncbi.nlm.nih.gov/24357341/) | Supports Treatment | Bisphosphonate +45% BMD, no new fractures |
| [11950061](https://pubmed.ncbi.nlm.nih.gov/11950061/), [28468609](https://pubmed.ncbi.nlm.nih.gov/28468609/) | Support Variant Spectrum | Truncating LOF predominance; TRPS I/II/III distinctions |
| [24709795](https://pubmed.ncbi.nlm.nih.gov/24709795/) | Supports Mechanism | Multi-target chondrogenic network (Sox9, Runx2, Stat3, Pthrp, Gli3) |
| [38899779](https://pubmed.ncbi.nlm.nih.gov/38899779/) | Supports Models | Hypomorphic mouse recapitulates postnatal hip pathology |

**Challenging/nuancing evidence:** The cancer literature ([PMID: 26969828](https://pubmed.ncbi.nlm.nih.gov/26969828/), [40197498](https://pubmed.ncbi.nlm.nih.gov/40197498/)) shows TRPS1 can be **context-dependently tumor-suppressive or oncogenic**, underscoring that "loss of function" is tissue-specific and that TRPS1 acts as both repressor and activator—caution against over-simplified LOF narratives.

---

## Limitations and Knowledge Gaps

1. **No systematic natural-history/QoL data** — formal EQ-5D/SF-36/PROMIS outcomes for TRPS I are unavailable; cohorts are small and retrospective.
2. **Epidemiology uncertainty** — prevalence estimates (~1/100,000; minimum 0.5/100,000) derive from small/single-center series; incidence unknown; underdiagnosis of mild cases is acknowledged.
3. **Mechanism mostly from mouse/in-vitro** — the RUNX2/Ihh/Wnt/Dspp causal chain is well supported in models but less directly validated in human tissue; several steps are **inferred**.
4. **No disease-specific epigenetic signature** has been defined.
5. **No OMIA/veterinary natural-disease counterpart** identified; comparative biology rests on engineered rodent models.
6. **Human modifier genetics** largely unexplored; *RUNX2* is a mouse modifier only.
7. **Therapy evidence is anecdotal** — rhGH and bisphosphonate data come from case reports/small series, not controlled trials; no targeted/molecular therapy exists.

## Proposed Follow-up Experiments / Actions

1. **Prospective multicenter TRPS registry** with standardized QoL instruments and longitudinal joint/skeletal outcomes to quantify natural history and GH/bisphosphonate efficacy.
2. **Patient-derived iPSC chondrocyte/organoid models** carrying truncating vs. GATA-domain-missense variants to directly test the haploinsufficiency vs. dominant-negative dichotomy on RUNX2/Ihh/SOX9 targets in human cells.
3. **Genome-wide TRPS1 ChIP-seq/CUT&RUN + RNA-seq** in human growth-plate chondrocytes and hair-follicle dermal papilla to map the direct target network and validate the dual repressor/activator model.
4. **Controlled or registry-based evaluation of bisphosphonates** for TRPS-associated osteoporosis, given the striking single-case +45% BMD response.
5. **Screen the RUNX2/Ihh and Wnt-inhibitor axes for druggable nodes** (e.g., Ihh-pathway modulation) using the Trps1^Δint hypomorphic mouse as a preclinical platform for hip-dysplasia/osteoarthrosis prevention.
6. **Define exon-6 missense dominant-negative mechanism** biochemically (DNA-binding, co-repressor recruitment) to support variant classification and prognostic counseling.

---

*Report compiled from 12 confirmed findings and 53 reviewed papers across 5 investigation iterations. Evidence types: human clinical cohorts/case reports, mouse/rat model-organism studies, and in-vitro functional assays, as annotated throughout.*


## Artifacts

- [OpenScientist final report](Trichorhinophalangeal_Syndrome_Type_I-deep-research-openscientist_artifacts/final_report.html)
- [OpenScientist final report](Trichorhinophalangeal_Syndrome_Type_I-deep-research-openscientist_artifacts/final_report.pdf)

## Reference Validation

Checked with `linkml-reference-validator` 0.3.0.

| Outcome | Count |
| --- | --- |
| References checked | 43 |
| Resolved | 43 |
| Unresolved (possible confabulation) | 0 |
| Unverifiable | 0 |
| Quoted claims checked | 4 |
| Quoted claims found in source | 4 |
| Quoted claims **not** found in source | 0 |
| References weighed for topical relevance | 43 |
| On topic | 30 |
| Off topic | 0 |

All extracted references resolved successfully.

## Term Validation

Checked with `linkml-term-validator` 0.4.5, through the `ols:` adapter.

| Outcome | Count |
| --- | --- |
| Terms checked | 43 |
| Resolved | 39 |
| Unresolved (possible confabulation) | 0 |
| Obsolete | 0 |
| Unverifiable | 4 |
| Terms whose name was checked | 16 |
| Terms named correctly | 7 |
| Terms named as a **different** term | 8 |
| Terms whose name is worth a second look | 1 |

### Terms the report names something else

These identifiers resolve, so nothing about them looks wrong, and the ontology calls them something unrelated to what the report calls them. That usually means the identifier is not the one the sentence needs:

- `MONDO:0008596` (2 mentions) - the report calls it "MONDO"; MONDO calls it **trichorhinophalangeal syndrome type I**
- `HP:0045025` (1 mention) - the report calls it "lateral eyebrow thinning"; HP calls it **Narrow palpebral fissure**
- `NCIT:C1898` (1 mention) - the report calls it "Recombinant Human Growth Hormone"; NCIT calls it **Physical Carcinogens**
- `NCIT:C1476` (1 mention) - the report calls it "Bisphosphonate"; NCIT calls it **Denileukin Diftitox**
- `NCIT:C47641` (1 mention) - the report calls it "Minoxidil"; NCIT calls it **Orphenadrine Citrate**
- `NCIT:C15300` (1 mention) - the report calls it "Orthopedic Surgery"; NCIT calls it **Photodynamic Therapy**
- `NCIT:C51818` (1 mention) - the report calls it "Tooth Extraction"; NCIT calls it **Coordinating Investigator**
- `NCIT:C15648` (1 mention) - the report calls it "Genetic Counseling"; NCIT calls it **Continuous Infusion Procedure**

### Terms whose name is worth a second look

The report's name for these is recognisably related to the term's own name without being one of them. A loose paraphrase reads the same way as a citation of the wrong sibling term - and so does a *related* synonym, which the ontology records precisely because it names something adjacent rather than the same thing - so these are listed rather than judged:

- `HP:0002213` (1 mention) - the report calls it "sparse hair"; HP calls it **Fine hair**

### Prefixes with no resolver

Terms carrying these prefixes were not checked either way, because no configured ontology covers them. An unrecognised prefix may name an ontology this run could not reach as easily as one that does not exist, so nothing here is evidence of fabrication: `ORPHA`, `Taxon`.